Literature DB >> 17056640

Confidence intervals for biomarker-based human immunodeficiency virus incidence estimates and differences using prevalent data.

Stephen R Cole1, Haitao Chu, Ron Brookmeyer.   

Abstract

Prevalent biologic specimens can be used to estimate human immunodeficiency virus (HIV) incidence using a two-stage immunologic testing algorithm that hinges on the average time, T, between testing HIV-positive on highly sensitive enzyme immunoassays and testing HIV-positive on less sensitive enzyme immunoassays. Common approaches to confidence interval (CI) estimation for this incidence measure have included 1) ignoring the random error in T or 2) employing a Bonferroni adjustment of the box method. The authors present alternative Monte Carlo-based CIs for this incidence measure, as well as CIs for the biomarker-based incidence difference; standard approaches to CIs are typically appropriate for the incidence ratio. Using American Red Cross blood donor data as an example, the authors found that ignoring the random error in T provides a 95% CI for incidence as much as 0.26 times the width of the Monte Carlo CI, while the Bonferroni-box method provides a 95% CI as much as 1.57 times the width of the Monte Carlo CI. Further research is needed to understand under what circumstances the proposed Monte Carlo methods fail to provide valid CIs. The Monte Carlo-based CI may be preferable to competing methods because of the ease of extension to the incidence difference or to exploration of departures from assumptions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056640     DOI: 10.1093/aje/kwj344

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  5 in total

1.  Relating recent infection prevalence to incidence with a sub-population of assay non-progressors.

Authors:  Thomas Andrew McWalter; Alex Welte
Journal:  J Math Biol       Date:  2009-07-25       Impact factor: 2.259

2.  Cross-sectional HIV incidence estimation in an evolving epidemic.

Authors:  Doug Morrison; Oliver Laeyendecker; Ron Brookmeyer
Journal:  Stat Med       Date:  2019-05-21       Impact factor: 2.373

3.  Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial.

Authors:  Stephen R Cole; Elizabeth A Stuart
Journal:  Am J Epidemiol       Date:  2010-06-14       Impact factor: 4.897

4.  Cross-sectional HIV incidence estimation in HIV prevention research.

Authors:  Ron Brookmeyer; Oliver Laeyendecker; Deborah Donnell; Susan H Eshleman
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07       Impact factor: 3.731

5.  Estimation of HIV incidence using multiple biomarkers.

Authors:  Ron Brookmeyer; Jacob Konikoff; Oliver Laeyendecker; Susan H Eshleman
Journal:  Am J Epidemiol       Date:  2013-01-09       Impact factor: 4.897

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.